logo
Trump's Order Targeting Jenner & Block Was Unconstitutional, Judge Rules

Trump's Order Targeting Jenner & Block Was Unconstitutional, Judge Rules

New York Times23-05-2025
A federal judge on Friday struck down an executive order signed by President Trump that threatened penalties against the law firm Jenner & Block, which once employed a top attorney who helped investigate the president alongside the team run by Robert S. Mueller III, who was then the special counsel.
It was the second time a federal judge found one of Mr. Trump's orders targeting elite law firms unconstitutional, after another judge ruled earlier in May that an essentially identical order targeting the firm Perkins Coie appeared retributive and designed to strong-arm the firm into serving the White House. Two other firms — WilmerHale and Susman Godfrey — have asked for similarly decisive rulings in lawsuits they brought.
In March, after a string of similar orders that openly detailed the president's political grievances and furthered his campaign of retribution, Mr. Trump released an order targeting Jenner & Block, citing its past decision to hire Andrew Weissmann after the special counsel's investigation of Russian interference in the 2016 election. Mr. Weissman left the firm in 2021.
The order leveraged the full force of the federal government to curtail Jenner & Block's business.
In an opinion on Friday, Judge John D. Bates wrote that the orders were 'doubly violative of the Constitution.' Not only did they violate the First Amendment by seeking to muzzle a perceived critic of the president, he wrote, they also had the effect of intimidating all other lawyers whose work 'protects against governmental viewpoint becoming government-imposed orthodoxy.'
'This case arises from one of a series of executive orders targeting law firms that, in one way or another, did not bow to the current presidential administration's political orthodoxy,' he wrote. 'Like the others in the series, this order — which takes aim at the global law firm Jenner & Block — makes no bones about why it chose its target: it picked Jenner because of the causes Jenner champions, the clients Jenner represents, and a lawyer Jenner once employed.'
The order had directed federal agencies to identify and cancel contracts with the firm, suspend security clearances held by its lawyers and bar its staff from federal buildings, all in the name of 'national security and other interests of the United States.'
Around the same time that Mr. Trump began releasing the orders, a cluster of other top firms rushed to pre-emptively head off retaliation by offering millions of dollars of pro bono work on areas of common ground, where they said the values of the firm and the White House appeared to align.
Between white shoe firms such as Paul Weiss, Skadden, Latham & Watkins and half a dozen others, the White House secured pledges approaching $1 billion worth of free work.
But a minority of firms, including Jenner & Block, Susman Godfrey and WilmerHale, went in the opposite direction and sued to stop the orders, arguing that they were clearly coercive. In court, lawyers pointed out that the moment other firms cut deals, the grave national security concerns cited in the executive orders abruptly vanished.
With Judge Bates's order on Friday, federal judges have so far agreed.
Permanently barring the government from enforcing the order, Judge Bates noted that the larger legal profession now faced a 'forward-looking censorship scheme,' in which the threat of punishment could be trotted out repeatedly, any time any firm appeared to be resisting Mr. Trump's political agenda.
'The administration has shown a repeated willingness to haggle, sending the message loud and clear that Jenner can spare itself — if it compromises its speech,' Judge Bates wrote. 'So whereas retaliation usually punishes once and moves along, the retaliation here is ongoing and avoidable.'
Last week, Jenner & Block's lawyers notified the court that despite the lawsuit challenging the terms of the executive order, several of its lawyers had since received letters informing them that their security clearances were being suspended anyway.
At the same time, firms that reached a deal have seen the scope of their agreements broaden, as Mr. Trump has reportedly mused about deploying those firms toward political causes such as renegotiating trade deals.
While Jenner & Block had asked Judge Bates to go beyond striking down the executive order and also block any future actions that could arise from the president's attacks, Judge Bates declined to do so.
Noting that he was 'very sympathetic' and even found it plausible that the government would retaliate again given its continual hounding of the firm during the litigation, he wrote that it was beyond the court's power to halt 'hypothetical future actions,' even if they were likely unconstitutional follow-up attacks.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hudbay Minerals (HBM) Climbs 15% on Stellar Earnings, $600-Million Investment From Mitsubishi
Hudbay Minerals (HBM) Climbs 15% on Stellar Earnings, $600-Million Investment From Mitsubishi

Yahoo

time23 minutes ago

  • Yahoo

Hudbay Minerals (HBM) Climbs 15% on Stellar Earnings, $600-Million Investment From Mitsubishi

We recently published . Hudbay Minerals Inc. (NYSE:HBM) is one of the best-performing stocks on Wednesday. Hudbay Minerals grew its share prices for a second day on Wednesday, up 15.03 percent to close at $11.33 apiece, following an impressive earnings performance and a $600-million investment from Mitsubishi Corp. In its updated report, Hudbay Minerals Inc. (NYSE:HBM) said it swung to a net income attributable to shareholders of $117.7 million from an attributable net loss of $16.5 million in the same period last year, driven by higher gross margins and strong cost control. Revenues increased by 26 percent to $536.4 million from $425.5 million year-on-year. 'With the strong performance in the first half of the year, we are reaffirming our full year consolidated production guidance and are favourably tracking well below our full year consolidated cost guidance for 2025,' said Hudbay Minerals Inc. (NYSE:HBM) President and CEO Peter Kukielski. For the full-year period, the company is targeting to produce between 117,000 and 149,000 tons of copper, as well as 247,500 to 308,000 ounces of gold. In other news, Hudbay Minerals Inc. (NYSE:HBM) was able to raise $600 million in fresh funds from Mitsubishi Corp. after the latter acquired a 30-percent stake in Copper World LLC. Under the agreement, Mitsubishi will pay an upfront cash of $420 million, with the balance to serve as a matching contribution within an 18-month period. While we acknowledge the potential of HBM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?
Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?

Yahoo

time23 minutes ago

  • Yahoo

Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?

We recently published . Paramount Skydance Corp. (NASDAQ:PSKY) is one of the best-performing stocks on Wednesday. Paramount Skydance extended its rally to touch a new high on Wednesday, finishing up by 36.74 percent at $15 apiece, with a former hedge fund manager calling it a 'meme' stock. In a social media post, Mad Money host and former hedge fund manager Jim Cramer said Paramount Skydance Corp. (NASDAQ:PSKY) is a 'meme stock' given the company's small public float and unjustifiable rally amid the lack of fresh developments. Paramount Skydance Corp. (NASDAQ:PSKY) climbed by as high as 60 percent at intra-day trading to hit $17.53 before paring gains to finish slightly lower during the session. In recent news, the company bagged a new $7.7-billion deal to exclusively air the Ultimate Fighting Championship (UFC) on Paramount+ for seven years beginning in 2026. The deal would include UFC's full slate of 13 marquee numbered events and 30 Fight Nights through its direct-to-consumer streaming platform, Paramount+, with select numbered events to be simulcast on CBS. cellanr, CC BY-SA 2.0 , via Wikimedia Commons As part of the agreement, Paramount Skydance Corp. (NASDAQ:PSKY) will move UFC away from the existing Pay-Per-View model and make the latter available at no additional cost to Paramount+ subscribers in the US. It also intends to explore UFC rights outside the US in the future. While we acknowledge the potential of PSKY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results

Yahoo

time23 minutes ago

  • Yahoo

ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results

We recently published . ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best-performing stocks on Wednesday. ImmunityBio soared by 14.17 percent on Wednesday to close at $2.82 apiece as investors cheered promising early findings from its ongoing trial (QUILT-106) to treat a rare blood cancer type with its therapy candidate. In a statement, ImmunityBio, Inc. (NASDAQ:IBRX) said the first phase of QUILT-106 showed highly promising results in the first two patients with Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy. The trial aims to evaluate the safety and efficacy of the cell therapy alone, as well as when it is combined with an existing drug called rituximab. According to ImmunityBio, Inc. (NASDAQ:IBRX), both patients tolerated the therapy candidate without any significant side effects. Notably, all infusions were administered in an outpatient setting. Copyright: katrintimoff / 123RF Stock Photo 'One patient achieved a complete response (CR) with CD19 CAR NK monotherapy, while the second patient achieved CR with CD19 CAR-NK in combination with rituximab. Remission was maintained and is ongoing for six months to date,' ImmunityBio, Inc. (NASDAQ:IBRX) said. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store